{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:30:52Z","timestamp":1790044252670,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10120-025-01700-z","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:48:37Z","timestamp":1767779317000},"page":"433-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic factors in patients with gastric cancer and positive peritoneal cytology who underwent upfront surgery"],"prefix":"10.1007","volume":"29","author":[{"given":"Takashi","family":"Abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2967-8267","authenticated-orcid":false,"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Koseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"5","key":"1700_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1245\/ASO.2005.03.065","volume":"12","author":"D Bentrem","year":"2005","unstructured":"Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12(5):347\u201353.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1700_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0002-9610(99)00162-2","volume":"178","author":"E Bando","year":"1999","unstructured":"Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg. 1999;178(3):256\u201362.","journal-title":"Am J Surg"},{"issue":"Suppl 1","key":"1700_CR3","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1007\/s10120-011-0071-z","volume":"15","author":"PA Leake","year":"2012","unstructured":"Leake PA, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S27-37.","journal-title":"Gastric Cancer"},{"issue":"2","key":"1700_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"Japanese Gastric Cancer A","year":"2011","unstructured":"Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101\u201312.","journal-title":"Gastric Cancer"},{"issue":"7","key":"1700_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(17)30438-2","volume":"18","author":"B O'Sullivan","year":"2017","unstructured":"O\u2019Sullivan B, Brierley J, Byrd D, Bosman F, Kehoe S, Kossary C, et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol. 2017;18(7):849\u201351.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1700_CR6","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1700_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10120-020-01137-6","volume":"24","author":"T Yamaguchi","year":"2021","unstructured":"Yamaguchi T, Takashima A, Nagashima K, Terashima M, Aizawa M, Ohashi M, et al. Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study. Gastric Cancer. 2021;24(3):701\u20139.","journal-title":"Gastric Cancer"},{"issue":"2","key":"1700_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2022;6(2):227\u201340.","journal-title":"Ann Gastroenterol Surg"},{"issue":"2","key":"1700_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10120-019-00994-0","volume":"23","author":"I Yasufuku","year":"2020","unstructured":"Yasufuku I, Nunobe S, Ida S, Kumagai K, Ohashi M, Hiki N, et al. Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. Gastric Cancer. 2020;23(2):319\u201327.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1700_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12957-022-02512-6","volume":"20","author":"A Yago","year":"2022","unstructured":"Yago A, Haruta S, Ueno M, Ogawa Y, Shimoyama H, Ohkura Y, et al. Clinical significance of initial treatment for peritoneal lavage cytology-positive gastric cancer: outcomes according to treatment strategy. World J Surg Oncol. 2022;20(1):35.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"1700_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10120-012-0156-3","volume":"15","author":"Y Kodera","year":"2012","unstructured":"Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, Kobayashi D, et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15(3):335\u20137.","journal-title":"Gastric Cancer"},{"issue":"11","key":"1700_CR12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.ejso.2009.03.003","volume":"35","author":"Y Kodera","year":"2009","unstructured":"Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, et al. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol. 2009;35(11):1158\u201363.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"1700_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer A","year":"2023","unstructured":"Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1700_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1245\/s10434-019-07697-x","volume":"27","author":"T Yamaguchi","year":"2020","unstructured":"Yamaguchi T, Takashima A, Nagashima K, Makuuchi R, Aizawa M, Ohashi M, et al. Efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology (CY1) or localized peritoneum metastasis (P1a): a multicenter retrospective study. Ann Surg Oncol. 2020;27(1):284\u201392.","journal-title":"Ann Surg Oncol"},{"issue":"18","key":"1700_CR15","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810\u201320.","journal-title":"N Engl J Med"},{"issue":"15","key":"1700_CR16","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296\u2013304.","journal-title":"J Clin Oncol"},{"issue":"9813","key":"1700_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315\u201321.","journal-title":"Lancet"},{"issue":"3","key":"1700_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1700_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10120-007-0436-5","volume":"10","author":"Y Fujiwara","year":"2007","unstructured":"Fujiwara Y, Doki Y, Taniguchi H, Sohma I, Takiguchi S, Miyata H, et al. Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives. Gastric Cancer. 2007;10(4):197\u2013204.","journal-title":"Gastric Cancer"},{"issue":"3-4","key":"1700_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000236018","volume":"77","author":"C Li","year":"2009","unstructured":"Li C, Oh SJ, Kim S, Hyung WJ, Yan M, Zhu ZG, et al. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology. 2009;77(3\u20134):197\u2013204.","journal-title":"Oncology"},{"issue":"1","key":"1700_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12957-020-01987-5","volume":"18","author":"XH Song","year":"2020","unstructured":"Song XH, Zhang WH, Kai L, Chen XL, Zhao LY, Chen XZ, et al. Prognostic impact of Borrmann classification on advanced gastric cancer: a retrospective cohort from a single institution in western China. World J Surg Oncol. 2020;18(1):204.","journal-title":"World J Surg Oncol"},{"issue":"5","key":"1700_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, et al. Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23(5):169\u201391.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01700-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01700-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01700-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:39:11Z","timestamp":1773905951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01700-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1700"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01700-z","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to remove the inadvertently included affiliation 2.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MT has received honorarium from Taiho Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Bristol Myers Squib Japan K.K.; Yakult Honsha Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; Pfizer Japan Inc.; Daiichi Sankyo Ltd.; Johnson and Johnson K.K.; Medtronic Japan Co., Ltd.; Intuitive Japan Inc.; and Olympus Co., Ltd. EB has received honorarium from Daiichi Sankyo Ltd.; Johnson and Johnson K.K.; Medtronic Japan Co., Ltd.; Intuitive Japan Inc.; Kaken Pharmaceutical; Eizo Co.; Terumo Co.; and Eizai Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were conducted in accordance with the ethical standards of the relevant institutional and national committees on human experimentation, as well as the 1964 Declaration of Helsinki and its later amendments. The study was approved by the Institutional Review Board of Shizuoka Cancer Center (approval number: 2022-173\u20132023-10). Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}